Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Van Den Anker JN et al. – Given the distributions of estimated creatinine clearance and weight between pre–term and full–term neonates, meropenem clearance was substantially higher in the full–term group. A Monte Carlo simulation was performed using the creatinine clearance and weight distributions for pre–term and full–term populations separately, examining 20– and 40–mg/kg doses, 8– and 12–h dosing intervals, and 0.5–h and 4–h infusion times. The 8–h interval produced robust target attainments (both populations). If more resistant organisms were to be treated (MIC of 4 to 8 mg/liter), the 40–mg/kg dose and a prolonged infusion was favored. Treating clinicians need to balance dose choices for optimizing target attainment against potential toxicity. These findings require validation in clinical circumstances.

Related Articles

Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii
Journal of Clinical Microbiology, 11/02/09    Relevance Score: 87%

Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates
American Journal of Infection Control, 11/12/09    Relevance Score: 80%

Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa
Antimicrobial Agents and Chemotherapy, 11/03/09    Relevance Score: 80%

Acute Granulomatous Acanthamoeba Encephalitis in an Immunocompetent Patient
Neurocritical Care, 10/26/09    Relevance Score: 80%

Today in Pharmacokinetics...keeping you current

Pharmacokinetics and safety of fibrinogen concentrate
Journal of Thrombosis and Haemostasis, 12/02/09

Impaired Renal Function and Opioid Toxicity
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09

Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long-Acting, Potent Glucagon-Like Peptide-1 Analog
Pharmacotherapy, 12/02/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address